Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

TALK vs DBVT vs ALKS vs OPRX vs INVA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TALK
Talkspace, Inc.

Medical - Care Facilities

HealthcareNASDAQ • US
Market Cap$868M
5Y Perf.-47.1%
DBVT
DBV Technologies S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$1712.35T
5Y Perf.-51.4%
ALKS
Alkermes plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$5.90B
5Y Perf.+96.6%
OPRX
OptimizeRx Corporation

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$124M
5Y Perf.-53.1%
INVA
Innoviva, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$1.93B
5Y Perf.+68.3%

TALK vs DBVT vs ALKS vs OPRX vs INVA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TALK logoTALK
DBVT logoDBVT
ALKS logoALKS
OPRX logoOPRX
INVA logoINVA
IndustryMedical - Care FacilitiesBiotechnologyBiotechnologyMedical - Healthcare Information ServicesBiotechnology
Market Cap$868M$1712.35T$5.90B$124M$1.93B
Revenue (TTM)$229M$0.00$1.56B$109M$424M
Net Income (TTM)$8M$-168M$153M$5M$504M
Gross Margin43.0%65.4%67.3%76.2%
Operating Margin1.4%12.3%10.7%14.8%
Forward P/E38.2x24.8x7.0x11.9x
Total Debt$0.00$22M$70M$5M$269M
Cash & Equiv.$37M$194M$1.12B$23M$551M

TALK vs DBVT vs ALKS vs OPRX vs INVALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

TALK
DBVT
ALKS
OPRX
INVA
StockJul 20May 26Return
Talkspace, Inc. (TALK)10052.9-47.1%
DBV Technologies S.… (DBVT)10048.6-51.4%
Alkermes plc (ALKS)100196.6+96.6%
OptimizeRx Corporat… (OPRX)10046.9-53.1%
Innoviva, Inc. (INVA)100168.3+68.3%

Price return only. Dividends and distributions are not included.

Quick Verdict: TALK vs DBVT vs ALKS vs OPRX vs INVA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: INVA leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Talkspace, Inc. is the stronger pick specifically for growth and revenue expansion. DBVT and OPRX also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
TALK
Talkspace, Inc.
The Growth Play

TALK is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 22.0%, EPS growth 6.5%, 3Y rev CAGR 24.2%
  • 22.0% revenue growth vs DBVT's -100.0%
Best for: growth exposure
DBVT
DBV Technologies S.A.
The Momentum Pick

DBVT ranks third and is worth considering specifically for momentum.

  • +110.4% vs OPRX's -30.1%
Best for: momentum
ALKS
Alkermes plc
The Quality Angle

Among these 5 stocks, ALKS doesn't own a clear edge in any measured category.

Best for: healthcare exposure
OPRX
OptimizeRx Corporation
The Value Play

OPRX is the clearest fit if your priority is value.

  • Lower P/E (7.0x vs 11.9x)
Best for: value
INVA
Innoviva, Inc.
The Income Pick

INVA carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • Dividend streak 0 yrs, beta 0.13
  • 94.9% 10Y total return vs ALKS's -11.0%
  • Lower volatility, beta 0.13, Low D/E 22.9%, current ratio 14.64x
  • Beta 0.13, current ratio 14.64x
Best for: income & stability and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthTALK logoTALK22.0% revenue growth vs DBVT's -100.0%
ValueOPRX logoOPRXLower P/E (7.0x vs 11.9x)
Quality / MarginsINVA logoINVA118.9% margin vs DBVT's 0.3%
Stability / SafetyINVA logoINVABeta 0.13 vs OPRX's 2.28
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)DBVT logoDBVT+110.4% vs OPRX's -30.1%
Efficiency (ROA)INVA logoINVA32.4% ROA vs DBVT's -89.0%

TALK vs DBVT vs ALKS vs OPRX vs INVA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

TALKTalkspace, Inc.

Segment breakdown not available.

DBVTDBV Technologies S.A.

Segment breakdown not available.

ALKSAlkermes plc
FY 2025
Vivitrol
39.8%$468M
Aristada And Aristada Initio
31.5%$370M
Manufactured Product And Royalty
24.8%$291M
Manufacturing Revenue
3.9%$46M
OPRXOptimizeRx Corporation

Segment breakdown not available.

INVAInnoviva, Inc.
FY 2025
Royalty
57.5%$236M
Product
41.8%$172M
License And Other Revenue
0.7%$3M

TALK vs DBVT vs ALKS vs OPRX vs INVA — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLOPRXLAGGINGALKS

Income & Cash Flow (Last 12 Months)

INVA leads this category, winning 5 of 6 comparable metrics.

ALKS and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. INVA is the more profitable business, keeping 118.9% of every revenue dollar as net income compared to TALK's 3.4%. On growth, TALK holds the edge at +29.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricTALK logoTALKTalkspace, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcOPRX logoOPRXOptimizeRx Corpor…INVA logoINVAInnoviva, Inc.
RevenueTrailing 12 months$229M$0$1.6B$109M$424M
EBITDAEarnings before interest/tax$7M-$112M$212M$16M$86M
Net IncomeAfter-tax profit$8M-$168M$153M$5M$504M
Free Cash FlowCash after capex-$2M-$151M$392M$12M$181M
Gross MarginGross profit ÷ Revenue+43.0%+65.4%+67.3%+76.2%
Operating MarginEBIT ÷ Revenue+1.4%+12.3%+10.7%+14.8%
Net MarginNet income ÷ Revenue+3.4%+9.8%+4.7%+118.9%
FCF MarginFCF ÷ Revenue-0.9%+25.1%+10.6%+42.8%
Rev. Growth (YoY)Latest quarter vs prior year+29.3%+28.2%-0.2%+10.6%
EPS Growth (YoY)Latest quarter vs prior year+91.5%-4.1%+4.0%
INVA leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

OPRX leads this category, winning 4 of 6 comparable metrics.

At 6.9x trailing earnings, INVA trades at a 95% valuation discount to TALK's 129.5x P/E. On an enterprise value basis, OPRX's 6.5x EV/EBITDA is more attractive than TALK's 137.8x.

MetricTALK logoTALKTalkspace, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcOPRX logoOPRXOptimizeRx Corpor…INVA logoINVAInnoviva, Inc.
Market CapShares × price$868M$1712.35T$5.9B$124M$1.9B
Enterprise ValueMkt cap + debt − cash$830M$1712.35T$4.9B$105M$1.7B
Trailing P/EPrice ÷ TTM EPS129.50x-0.76x24.76x24.56x6.91x
Forward P/EPrice ÷ next-FY EPS est.38.20x7.04x11.91x
PEG RatioP/E ÷ EPS growth rate0.67x
EV / EBITDAEnterprise value multiple137.77x17.25x6.55x8.10x
Price / SalesMarket cap ÷ Revenue3.79x4.00x1.13x4.55x
Price / BookPrice ÷ Book value/share7.69x0.66x3.28x0.98x1.65x
Price / FCFMarket cap ÷ FCF12.28x6.62x9.88x
OPRX leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

Evenly matched — ALKS and INVA each lead in 3 of 9 comparable metrics.

INVA delivers a 46.5% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $-130 for DBVT. OPRX carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to INVA's 0.23x. On the Piotroski fundamental quality scale (0–9), OPRX scores 8/9 vs DBVT's 4/9, reflecting strong financial health.

MetricTALK logoTALKTalkspace, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcOPRX logoOPRXOptimizeRx Corpor…INVA logoINVAInnoviva, Inc.
ROE (TTM)Return on equity+6.9%-130.2%+8.8%+4.2%+46.5%
ROA (TTM)Return on assets+5.9%-89.0%+5.4%+3.0%+32.4%
ROICReturn on invested capital+3.9%+18.9%+7.1%+14.2%
ROCEReturn on capital employed+2.7%-145.7%+14.2%+7.6%+12.4%
Piotroski ScoreFundamental quality 0–964785
Debt / EquityFinancial leverage0.13x0.04x0.04x0.23x
Net DebtTotal debt minus cash-$37M-$172M-$1.0B-$19M-$282M
Cash & Equiv.Liquid assets$37M$194M$1.1B$23M$551M
Total DebtShort + long-term debt$0$22M$70M$5M$269M
Interest CoverageEBIT ÷ Interest expense-189.82x32.30x1.26x63.45x
Evenly matched — ALKS and INVA each lead in 3 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

TALK leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in INVA five years ago would be worth $19,437 today (with dividends reinvested), compared to $1,266 for OPRX. Over the past 12 months, DBVT leads with a +110.4% total return vs OPRX's -30.1%. The 3-year compound annual growth rate (CAGR) favors TALK at 80.7% vs OPRX's -23.0% — a key indicator of consistent wealth creation.

MetricTALK logoTALKTalkspace, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcOPRX logoOPRXOptimizeRx Corpor…INVA logoINVAInnoviva, Inc.
YTD ReturnYear-to-date+47.6%+4.9%+25.3%-46.6%+14.7%
1-Year ReturnPast 12 months+70.4%+110.4%+16.5%-30.1%+21.7%
3-Year ReturnCumulative with dividends+490.0%+19.7%+14.5%-54.4%+95.2%
5-Year ReturnCumulative with dividends-47.7%-69.1%+60.9%-87.3%+94.4%
10-Year ReturnCumulative with dividends-48.7%-87.0%-11.0%+110.5%+94.9%
CAGR (3Y)Annualised 3-year return+80.7%+6.2%+4.6%-23.0%+25.0%
TALK leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — TALK and INVA each lead in 1 of 2 comparable metrics.

INVA is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than OPRX's 2.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TALK currently trades 99.6% from its 52-week high vs OPRX's 29.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTALK logoTALKTalkspace, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcOPRX logoOPRXOptimizeRx Corpor…INVA logoINVAInnoviva, Inc.
Beta (5Y)Sensitivity to S&P 5000.86x1.26x1.06x2.28x0.13x
52-Week HighHighest price in past year$5.20$26.18$36.60$22.25$25.15
52-Week LowLowest price in past year$2.22$7.53$25.17$5.54$16.52
% of 52W HighCurrent price vs 52-week peak+99.6%+76.3%+96.7%+29.8%+90.7%
RSI (14)Momentum oscillator 0–10062.748.160.246.939.9
Avg Volume (50D)Average daily shares traded4.5M252K2.3M476K621K
Evenly matched — TALK and INVA each lead in 1 of 2 comparable metrics.

Analyst Outlook

OPRX leads this category, winning 1 of 1 comparable metric.

Analyst consensus: TALK as "Hold", DBVT as "Buy", ALKS as "Buy", OPRX as "Buy", INVA as "Buy". Consensus price targets imply 156.4% upside for OPRX (target: $17) vs 1.4% for TALK (target: $5).

MetricTALK logoTALKTalkspace, Inc.DBVT logoDBVTDBV Technologies …ALKS logoALKSAlkermes plcOPRX logoOPRXOptimizeRx Corpor…INVA logoINVAInnoviva, Inc.
Analyst RatingConsensus buy/hold/sellHoldBuyBuyBuyBuy
Price TargetConsensus 12-month target$5.25$46.33$44.00$17.00$37.67
# AnalystsCovering analysts1015281510
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises0010
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+2.0%0.0%+0.5%0.0%+0.2%
OPRX leads this category, winning 1 of 1 comparable metric.
Key Takeaway

OPRX leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). INVA leads in 1 (Income & Cash Flow). 2 tied.

Best OverallOptimizeRx Corporation (OPRX)Leads 2 of 6 categories
Loading custom metrics...

TALK vs DBVT vs ALKS vs OPRX vs INVA: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is TALK or DBVT or ALKS or OPRX or INVA a better buy right now?

For growth investors, Talkspace, Inc.

(TALK) is the stronger pick with 22. 0% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — TALK or DBVT or ALKS or OPRX or INVA?

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus Talkspace, Inc. at 129. 5x. On forward P/E, OptimizeRx Corporation is actually cheaper at 7. 0x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — TALK or DBVT or ALKS or OPRX or INVA?

Over the past 5 years, Innoviva, Inc.

(INVA) delivered a total return of +94. 4%, compared to -87. 3% for OptimizeRx Corporation (OPRX). Over 10 years, the gap is even starker: OPRX returned +110. 5% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — TALK or DBVT or ALKS or OPRX or INVA?

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus OptimizeRx Corporation's 2. 28β — meaning OPRX is approximately 1706% more volatile than INVA relative to the S&P 500. On balance sheet safety, OptimizeRx Corporation (OPRX) carries a lower debt/equity ratio of 4% versus 23% for Innoviva, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — TALK or DBVT or ALKS or OPRX or INVA?

By revenue growth (latest reported year), Talkspace, Inc.

(TALK) is pulling ahead at 22. 0% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, TALK leads at 24. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — TALK or DBVT or ALKS or OPRX or INVA?

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is TALK or DBVT or ALKS or OPRX or INVA more undervalued right now?

On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 7.

0x forward P/E versus 38. 2x for Talkspace, Inc. — 31. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 156. 4% to $17. 00.

08

Which pays a better dividend — TALK or DBVT or ALKS or OPRX or INVA?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is TALK or DBVT or ALKS or OPRX or INVA better for a retirement portfolio?

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). OptimizeRx Corporation (OPRX) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, OPRX: +110. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between TALK and DBVT and ALKS and OPRX and INVA?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TALK is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock; INVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

TALK

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Gross Margin > 25%
Run This Screen
Stocks Like

DBVT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ALKS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

OPRX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 40%
Run This Screen
Stocks Like

INVA

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 71%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.